-----BEGIN PRIVACY-ENHANCED MESSAGE----- Proc-Type: 2001,MIC-CLEAR Originator-Name: keymaster@town.hall.org Originator-Key-Asymmetric: MFkwCgYEVQgBAQICAgADSwAwSAJBALeWW4xDV4i7+b6+UyPn5RtObb1cJ7VkACDq pKb9/DClgTKIm08lCfoilvi9Wl4SODbR1+1waHhiGmeZO8OdgLUCAwEAAQ== MIC-Info: RSA-MD5,RSA, ieHV4vMT/REtEaaXkDeFiVGF4HB6rDrYKp6uWY8IxTbl088vrcJ27Bin3Qu5St5X YDOA3QuxY0NuhfgzA98UZw== 0000950103-95-000044.txt : 19950607 0000950103-95-000044.hdr.sgml : 19950607 ACCESSION NUMBER: 0000950103-95-000044 CONFORMED SUBMISSION TYPE: SC 13D/A PUBLIC DOCUMENT COUNT: 1 FILED AS OF DATE: 19950123 SROS: NONE SUBJECT COMPANY: COMPANY DATA: COMPANY CONFORMED NAME: GENENTECH INC CENTRAL INDEX KEY: 0000318771 STANDARD INDUSTRIAL CLASSIFICATION: MEDICINAL CHEMICALS & BOTANICAL PRODUCTS [2833] IRS NUMBER: 942347624 STATE OF INCORPORATION: DE FISCAL YEAR END: 1231 FILING VALUES: FORM TYPE: SC 13D/A SEC ACT: 1934 Act SEC FILE NUMBER: 005-32488 FILM NUMBER: 95502271 BUSINESS ADDRESS: STREET 1: 460 POINT SAN BRUNO BLVD CITY: SOUTH SAN FRANCISCO STATE: CA ZIP: 94080 BUSINESS PHONE: 4152251000 MAIL ADDRESS: STREET 1: * STREET 2: . FILED BY: COMPANY DATA: COMPANY CONFORMED NAME: ROCHE HOLDINGS INC CENTRAL INDEX KEY: 0000904566 STANDARD INDUSTRIAL CLASSIFICATION: UNKNOWN SIC - 0000 [0000] IRS NUMBER: 510304944 STATE OF INCORPORATION: DE FISCAL YEAR END: 1231 FILING VALUES: FORM TYPE: SC 13D/A BUSINESS ADDRESS: STREET 1: 15 EAST NORTH STREET CITY: DOVER STATE: DE ZIP: 19901 BUSINESS PHONE: 2124504336 MAIL ADDRESS: STREET 1: C/O DAVIS POLK & WARDWELL STREET 2: 450 LEXINGTON AVENUE CITY: NEW YORK STATE: NY ZIP: 10017 SC 13D/A 1 UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13D Under the Securities Exchange Act of 1934* (Amendment No. 8) GENENTECH, INC. (Name of Issuer) REDEEMABLE COMMON STOCK $.02 PAR VALUE (Title of Class of Securities) 368710208 ______________________________________________________________________________ (CUSIP Number) Peter R. Douglas Davis Polk & Wardwell 450 Lexington Avenue New York, NY 10017 Tel. No.: (212) 450-4000 ______________________________________________________________________________ (Name, Address and Telephone Number of Person Authorized to Receive Notices and Communications) January 19, 1995 ______________________________________________________________________________ (Date of Event which Requires Filing of this Statement) If the filing person has previously filed a statement on Schedule 13G to report the acquisition which is the subject of this Schedule 13D, and is filing this schedule because of Rule 13d-1(b)(3) or (4), check the following box [ ]. Check the following box if a fee is being paid with this statement. [ ] (A fee is not required only if the reporting person: (1) has a previous statement on file reporting beneficial ownership of more than five percent of the class of securities described in Item 1; and (2) has filed no amendment subsequent thereto reporting beneficial ownership of less than five percent of such class). (See Rule 13d-7.) Note: This document is being electronically filed with the Commission, using the EDGAR system. Additionally, one paper copy of the filing will subsequently be sent to the Commission. See Rule 13d-1(a) for other parties to whom copies are to be sent. *The remainder of this cover page should be filled out for a reporting person's initial filing on this form with respect to the subject class of securities, and for any subsequent amendment containing information which would alter disclosures provided in a prior cover page. The information required on the remainder of this cover page shall not be deemed to be "filed" for the purpose of Section 18 of the Securities Exchange Act of 1934 ("Act") or otherwise subject to the liabilities of that section of the Act but shall be subject to all other provisions of the Act (however, see the Notes). CUSIP No. 368710208 _________________________________________________________________ (1) Names of Reporting Persons S.S. or I.R.S. Identification Nos. of Above Persons ROCHE HOLDINGS, INC. 51-0304944 _________________________________________________________________ (2) Check the Appropriate Box if a Member of a Group (a) [ ] (b) [ ] _________________________________________________________________ (3) SEC Use Only _________________________________________________________________ (4) Source of Funds WC _________________________________________________________________ (5) Check if Disclosure of Legal Proceedings is Required Pursuant to Items 2(d) or 2(e) [ ] _________________________________________________________________ (6) Citizenship or Place of Organization United States of America _________________________________________________________________ Number of (7) Sole Voting Power 9,328,600 Shares Shares Bene- Redeemable Common Stock ficially Owned by- (8) Shared Voting Power 0 Shares Each Report- ing Person - (9) Sole Dispositive Power 9,328,600 Shares With Redeemable Common Stock (10) Shared Dispositive Power 0 Shares _____________________________________________________________________________ (11) Aggregate Amount Beneficially Owned by Each Reporting Person 9,328,600 Redeemable Common Stock _____________________________________________________________________________ (12) Check if the Aggregate Amount in Row (11) Excludes Certain Shares [ ] _____________________________________________________________________________ (13) Percent of Class Represented by Amount in Row (11) 18.9% of Redeemable Common Stock _____________________________________________________________________________ (14) Type of Reporting Person (See Instructions) CO, HC The following information amends and supplements the Schedule 13D dated September 17, 1990, as previously amended (as so amended, the "Schedule 13D"). Item 1. Security and Issuer. This statement relates to the Redeemable Common Stock, par value $.02 per share (the "Redeemable Common Stock" and, together with the Common Stock, par value $.02 per share (the "Common Stock"), the "Common Shares"), of Genentech, Inc., a Delaware corporation (the "Company"). The principal executive offices of the Company are located at 460 Point San Bruno Boulevard, San Francisco, California 94080. Item 2. Identity and Background. This statement is filed by Roche Holdings, Inc., a Delaware corporation ("Purchaser") and wholly owned subsidiary of Roche Finance Ltd, a Swiss corporation ("Finance") and wholly owned subsidiary of Roche Holding Ltd, a Swiss corporation ("Holding"). Dr. h.c. Paul Sacher, an individual and citizen of Switzerland ("Dr. Sacher") has, pursuant to an agreement, the power to vote a majority of the voting securities of Holding. Purchaser, Finance, Holding and Dr. Sacher are herein referred to collectively as the "Reporting Persons". The address of the principal offices of Purchaser is 15 East North Street, Dover, Delaware 19901. The address of the principal offices of Finance is Grenzacherstrasse 122, Basel, Switzerland. The address of the principal offices of Holding is Grenzacherstrasse 124, Basel 4002, Switzerland. The business address of Dr. Sacher is Haus auf Burg, Muensterplatz 4, Basel 4051, Switzerland. Item 3. Source and Amount of Consideration The aggregate purchase price for the 497,600 shares of Redeemable Common Stock acquired by Purchaser between January 10, 1995 and January 20, 1995 as described in Item 4 was $22,827,447.07, excluding commissions, and was financed from working capital of the Purchaser. Item 4. Purpose of Transaction Between January 10, 1995 and January 20, 1995, the Purchaser purchased an aggregate of 497,600 shares of Redeemable Common Stock for an aggregate purchase price of $22,827,447.07, excluding commissions. Certain information with respect to purchases of Redeemable Common Stock during the period following the filing of Amendment No. 7 to the Schedule 13D and preceding the date of this Amendment is set forth in Schedule D. Subject to market conditions and other factors (including limits imposed by the Governance Agreement between Purchaser and the Company), the Purchaser expects that it or its affiliates may acquire additional Redeemable Common Stock from time to time in the future in open-market, privately negotiated or other transactions. The purpose of the Purchaser, Finance and Holding in effecting the purchases of Redeemable Common Stock referred to above was to increase their aggregate equity interest in the Company. Item 5. Interest in the Securities of the Issuer. (a) The Purchaser is the beneficial owner of 67,133,409 shares of Common Stock (100% of the Common Stock outstanding) and 9,328,600 shares of Redeemable Common Stock (18.9% of the 49,473,045 shares of Redeemable Common Stock outstanding as of September 30, 1994 according to the Company's Form 10-Q for the quarter then ended (the "10-Q")), which together represent 65.6% of the 116,606,454 Common Shares outstanding as of September 30, 1994 according to the 10-Q. Transactions by the Reporting Persons in Redeemable Common Stock during the period following the filing of Amendment No. 7 to the Schedule 13D and preceding the date of this Amendment are described in Item 4 and in Schedule D. Except as set forth herein, neither the Reporting Persons nor any other person controlling the Reporting Parties nor, to the best of their knowledge, any of the persons named in Schedules A, B and C hereto beneficially owns any Common Shares, except that Prof. Jurgen Drews owns 200 shares of Redeemable Common Stock and Prof. Drews and Dr. Armin M. Kessler have each been granted employee stock options by the Company to purchase 15,000 shares of Redeemable Common Stock at $25.50 per share, all of which are issuable under currently exercisable stock options and options exercisable within sixty days of January 20, 1995, and 15,000 shares of Redeemable Common Stock at $26.50 per share, 10,000 of which are issuable under currently exercisable stock options and options exercisable within sixty days of January 20, 1995. (b) Except as otherwise described herein, none of the Reporting Persons has any sole or shared power to vote or to direct the vote of any Common Shares nor sole or shared power to dispose of or direct the disposition of any Common Shares. (c) Except as set forth herein and in Schedule D hereto and in Amendment No. 7 to the Schedule 13D, no transactions in the Common Shares have been effected during the past 60 days by the Reporting Persons nor any other person controlling the Reporting Persons nor, to the best of their knowledge, any of the persons named in Schedules A, B and C hereto. Item 6. Contracts, Arrangements, Understandings or Relationships with Respect to Securities of the Issuer. There are no contracts, arrangements, understandings or relationships among the persons named in Item 2 or between any of such persons and any other person with respect to any securities of the Company except as referred to or described in the Schedule 13D. Item 7. Material Filed as Exhibits. None. After reasonable inquiry and to the best of my knowledge and belief, I certify that the information set forth in this statement is true, complete and correct. Dated: January 23, 1995 ROCHE HOLDINGS, INC. By /s/ Henri B. Meier ________________________________ Name: Henri B. Meier Title: Vice President, Finance, Accounting SCHEDULE A Executive Officers and Directors(*) of Roche Holdings, Inc. The names of the Directors and the names and titles of the Executive Officers of Roche Holdings, Inc. and their business addresses and principal occupations are set forth below. If no address is given, the Director's or Executive Officer's business address is that of Roche Holding Ltd. Unless otherwise indicated, each occupation set forth opposite an individual's name refer to Roche Holding Ltd and each individual is a Swiss citizen. Present Principal Name, Business Address Occupation ______________________ _____________________ *Mr. Fritz Gerber Chairman, President and (President) Chief Executive Officer *Dr. Henri B. Meier Chief Financial Officer SCHEDULE B Executive Officers and Directors(*) of Roche Finance Ltd The names of the Directors and the names and titles of the Executive Officers of Roche Finance Ltd and their business addresses and principal occupations are set forth below. If no address is given, the Director's or Executive Officer's business address is that of Roche Holding Ltd. Unless otherwise indicated, each occupation set forth opposite an individual's name refers to Roche Holding Ltd and each individual is a Swiss citizen. Present Principal Name, Business Address Occupation ______________________ __________________________ *Mr. Fritz Gerber Chairman of the Board, (President) President and Chief Executive Officer *Dr. Andres F. Leuenberger Vice Chairman of the Board *Dr. Henri B. Meier Chief Financial Officer SCHEDULE C Executive Officers and Directors(*) of Roche Holding Ltd The names of the Directors and the names and titles of the Executive Officers of Roche Holding Ltd and their business addresses and principal occupations are set forth below. If no address is given, the Director's or Executive Officer's business address is that of Roche Holding Ltd. Unless otherwise indicated, each occupation set forth opposite an individual's name refers to Roche Holding Ltd and each individual is a Swiss citizen, except that Dr. Drews is a German citizen and Mr. Belingard is a French citizen. Present Principal Name, Business Address Occupation ______________________ ____________________ *Mr. Fritz Gerber Chairman of the Board and Chief Executive Officer *Dr. Lukas Hoffmann Vice Chairman of the Board Le petit Essert Vice Chairman of WWF 1147 Montricher, Switzerland International (a nonprofit organization) *Dr. Andres F. Leuenberger Vice Chairman and Delegate of the Board *Dr. h.c. Paul Sacher Conductor and Founder of Haus auf Burg Paul Sacher Foundation Muensterplatz 4 (a nonprofit organization) 4051 Basel, Switzerland *Dr. Armin M. Kessler Chief Operating Officer *Dr. Henri B. Meier Chief Financial Officer *Dr. Jakob Oeri Surgeon and retired Director Head Physician, St. Alban - Vorstadt 71 Kantonsspital Basel (hospital) *Dr. Kurt Jenny Lawyer Aeschengraben 18 4051 Basel, Switzerland Prof. Dr. Werner Stauffacher Professor Head of Department University of Basel of Internal Medicine Hebelstrasse 32 4056 Basel, Switzerland *Prof. Charles Weissmann Professor Director University of Zurich Institut fur Molekularbiologie I der Universitaet Zurich Hoenggerberg 8093 Zurich, Switzerland Dr. Markus Altwegg General Manager Dr. Roland Bronnimann General Manager Prof. Jurgen Drews General Manager Mr. Jean-Luc Belingard General Manager SCHEDULE D(*) Purchases of Redeemable Common Stock (transactions effected on NYSE except as noted) (all prices exclude commissions) Date Number of Shares Price Per Share ____ ________________ _______________ 1-11-95 7,700 $46.25 53,100 $46.375 16,700 $46.50 38,400 $46.375(**) 1-12-95 14,900 $46.125 10,300 $46.25 1,100 $46.375 3,700 $46.50 29,000 $46.125(**) 9,900 $46.375(**) 1-13-95 13,900 $45.875 42,600 $46.00 28,100 $46.125 1,800 $46.25 9,000 $46.125(**) 32,400 $46.1875(**) 1-16-95 1,000 $46.25 3,000 $46.375 6,500 $46.50 1-19-95 2,000 $44.625 23,000 $44.75 15,000 $44.875 1,000 $45.00 4,700 $45.125 62,300 $45.25 9,000 $45.375 56,300 $45.50 1,200 $45.3125(**) _______________ (*) Additional purchases within the 60 days preceding the date of this Amendment were reported in Schedule D to Amendment 7 to the Schedule 13D. (**) Executed in the third market. -----END PRIVACY-ENHANCED MESSAGE-----